NYSE:CO Global Cord Blood (CO) Stock Price, News & Analysis $1.75 0.00 (0.00%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$1.75▼$2.0050-Day Range$1.00▼$1.7552-Week Range$2.03▼$5.50Volume3,283 shsAverage Volume216,519 shsMarket Capitalization$212.71 millionP/E Ratio2.73Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends Get Global Cord Blood alerts: Email Address Ad Insiders Exposed$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Global Cord Blood Stock (NYSE:CO)Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Read More CO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CO Stock News HeadlinesAugust 18, 2024 | msn.comNearly 14,000 alleging Covid vaccines harm apply for compensationAugust 18, 2024 | americanbankingnews.comGlobal Cord Blood (NYSE:CO) Coverage Initiated at StockNews.comAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 17, 2024 | msn.comAlmost 14,000 seek compensation, saying Covid vaccines left them disabledAugust 14, 2024 | finance.yahoo.comIV Pole Market is Expected to Reach USD 361.0 Million by 2034 And Grow at A CAGR Rate of 3.5% | Future Market Insights, Inc.August 9, 2024 | msn.comSaccharin Sugar Substitute: What to KnowAugust 6, 2024 | msn.comGCBC's joint liquidators sell full stake in Cordlife GroupJuly 22, 2024 | msn.comMultiple Sclerosis Explained: How To Spot Early Warning SignsAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 19, 2024 | msn.comHealth Matters: Cord Blood Donation MonthJune 24, 2024 | globenewswire.comCO, CORBF DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBFJune 22, 2024 | prnewswire.comCO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud LawsuitJune 21, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global CordJune 20, 2024 | globenewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBFJune 16, 2024 | globenewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBFJune 14, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Global Cord Blood Corporation (CORBF)June 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBFJune 12, 2024 | globenewswire.comROSEN, A LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBFSee More Headlines Receive CO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global Cord Blood and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/26/2018Today8/22/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSE:CO CUSIPN/A CIK1467808 Webwww.globalcordbloodcorp.com Phone(523) 605-8180Fax852-3605-8181Employees1,202Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio2.73 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.24 billion Price / Sales0.17 Cash Flow$0.42 per share Price / Cash Flow4.19 Book Value$6.34 per share Price / Book0.28Miscellaneous Outstanding Shares121,551,000Free FloatN/AMarket Cap$212.71 million OptionableNo Data Beta0.16 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesTing ZhengChairman & Chief Executive OfficerBing Chuen ChenChief Financial Officer & DirectorXin XuChief Technology OfficerRui ArashiyamaCEO-Guangdong & Zhejiang DivisionsKey CompetitorsViemed HealthcareNASDAQ:VMDGlobal Cord BloodNYSE:CORBFBioRestorative TherapiesNASDAQ:BRTXOntrakNASDAQ:OTRKMangoceuticalsNASDAQ:MGRXView All Competitors CO Stock Analysis - Frequently Asked Questions How have CO shares performed this year? Global Cord Blood's stock was trading at $1.22 on January 1st, 2024. Since then, CO shares have increased by 43.4% and is now trading at $1.75. View the best growth stocks for 2024 here. How were Global Cord Blood's earnings last quarter? Global Cord Blood Co. (NYSE:CO) issued its quarterly earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. How do I buy shares of Global Cord Blood? Shares of CO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Global Cord Blood own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global Cord Blood investors own include AbbVie (ABBV), Fate Therapeutics (FATE), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), Vertex Pharmaceuticals (VRTX) and Enphase Energy (ENPH). This page (NYSE:CO) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
